Study of the Value of Using a Honey Dressing Compared to the Use of a Standard Dressing on the Toe Amputation Wound in the Diabetic Patient

Overview

Numerous scientific publications in France and internationally have described the healing, anti-bacterial, anti-oxidant, anti-inflammatory and immuno-modulating properties of honey. Honey is effective in the management of many infected or uninfected post-surgical wounds. This study focuses on post surgical wounds after toe amputation in diabetic patients. The main objective of this study is to compare the rate of epidermisation at six months for these wounds, between honey dressing and other dressing devices used according to the french Haute Autorité de Santé (HAS) recommendations

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 8, 2021

Interventions

  • Device: Honey dressing Melectis G
    • The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing. Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended.
  • Device: HAS recommendation dressing
    • Patients included in the standard arm will receive the best available dressing according to the HAS recommendations. Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended.

Arms, Groups and Cohorts

  • Active Comparator: HAS dressing
    • Patients included in the “HAS dressing” arm will receive the best available dressing according to the HAS recommendations. HAS is the french National Authority for Health (HAS) .
  • Experimental: Honey dressing
    • the honey used in this study is the Melectis G dressing. This is a combination of thyme honey (99.8%) and hyaluronic acid (0.2%). The patient will benefit from the honey dressing until complete healing and/or until the end of the study (maximum 12 months).

Clinical Trial Outcome Measures

Primary Measures

  • Epidermization rate at 6 months.
    • Time Frame: 6 months after amputation
    • the relative difference between the volume of the wound in mm3 during the first rehabilitation of the post-operative dressing (J0) and this volume six months after (M6), on the volume of the wound in mm3 at J0. (TM6 = (VD0 – VM6) /VD0)

Secondary Measures

  • Epidermization rate at 12 months
    • Time Frame: 12 months after amputation
    • the relative difference between the volume of the wound in mm3 during the first rehabilitation of the post-operative dressing (J0) and this volume 12 months after (M12), on the volume of the wound in mm3 at J0. (T = (VD0 – VM12) /VD0)
  • pain during dressing change: verbal scale of pain
    • Time Frame: inclusion, 1month, 2 months, 3months, 4months, 5 months, 6 months,7months,8months, 8months ,9months 10months, 11months, 12 months after amputation up to cicatrization
    • verbal scale of pain. this scale measures the pain of patient. the ranges are 0 to 4.
  • average length of wound cicatrization
    • Time Frame: from date of amputation until the date of the first documented complete cicatrization, assessed up to 12 months
    • The average length of wound healing in case of complete healing before the end of the study.
  • the satisfaction of professionals for the use of honey dressing
    • Time Frame: 12 months after amputation or at study completion, whichever came first
    • the level of satisfaction of all professionals involved in the rehabilitation of the honey dressing, will be evaluated with a Likert scale.The Likert scale, which falls under our definition of a survey scale, is a 5 point scale that ranges from one extreme attitude to another, like “extremely likely” to “not at all likely.” They include a moderate or neutral midpoint.
  • Epidermization rate at 1 month
    • Time Frame: 1 month after amputation
    • the relative difference between the volume of the wound in mm3 during the first rehabilitation of the post-operative dressing (J0) and this volume 1 month after (M1), on the volume of the wound in mm3 at J0. (T = (VD0 – VM1) /VD0)
  • Epidermization rate at 2 months
    • Time Frame: 1 month after amputation
    • the relative difference between the volume of the wound in mm3 during the first rehabilitation of the post-operative dressing (J0) and this volume 2 months after (M2), on the volume of the wound in mm3 at J0. (T = (VD0 – VM2) /VD0)

Participating in This Clinical Trial

Inclusion Criteria

  • Diabetic patients – Patients who have had an amputation of one or more toes within four days prior to inclusion without having the second dressing rehabilitated – Written informed consent. Exclusion Criteria:

  • Known hypersensitivity to honey, hyaluronic acid, guar gum, pectin and/or zinc oxide. – Insipid Diabètes – patient eligible for a dressing by Vacuum Assisted Closure therapy (VAC therapy) – transmetatarsal amputation – Patient with sutured wound – Patient already included in the study, for a previous amputation for wich the wound has not healed. – Failure to comply with protocol requirements – Person protect by article L1121-5 to L1121-8 of the French Health Public. – Patient include in an other clinical study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Metropole Savoie
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.